sulfadiazine has been researched along with HIV Coinfection in 14 studies
Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.
diazine : The parent structure of the diazines.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No differences in pharmacokinetic parameters were detected between the regimens." | 2.71 | Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients. ( Alfaro, RM; Burstein, AH; Jordan, MK; Kovacs, JA; Pau, AK; Piscitelli, SC; Rock-Kress, D, 2004) |
| "11), and drug discontinuation because of adverse events (P-C: RR 0." | 2.55 | A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option? ( Benites-Zapata, VA; Deshpande, A; Hernandez, AV; Pasupuleti, V; Pellegrino, D; Penalva de Oliveira, AC; Thota, P; Vidal, JE, 2017) |
| "Severe forms of cerebral toxoplasmosis in patients with HIV infection are characterized by a good prognosis in approximately 50% of cases." | 1.38 | Neurologic outcomes and adjunctive steroids in HIV patients with severe cerebral toxoplasmosis. ( Ait Hssain, A; Bouadma, L; da Silva, D; Klein, IF; Messika, J; Mourvillier, B; Schmidt, M; Sonneville, R; Wolff, M, 2012) |
| "Sulfadiazine-nephropathy and -nephrolithiasis were well known complications of high dose sulfadiazine therapy 50 years ago." | 1.29 | [Sulfadiazine nephrolithiasis and nephropathy]. ( Furrer, H; Hess, B; Jaeger, P; von Overbeck, J, 1994) |
| "ET was the AIDS-defining condition in 44% of the patients." | 1.29 | [Cerebral toxoplasmosis in patients with human immunodeficiency virus (HIV) infection. Clinico-radiological and therapeutic aspects in 63 patients]. ( Barrio, JL; Cadafalch, J; Domingo, P; Ferrer, S; Fuentes, I; Fuster, M; Iranzo, A; Muñoz, C; Nolla, J; Ris, J; Sambeat, MA, 1996) |
| "18 for the 50-mg/day and 25-mg/day dosage of pyrimethamine, respectively." | 1.28 | Ocular toxoplasmosis in human immunodeficiency virus-infected patients. ( Cochereau-Massin, I; Girard, B; Katlama, C; Lautier-Frau, M; LeHoang, P; Leport, C; Marcel, P; Robinet, M; Zazoun, L; Zerdoun, E, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Zeng, YM | 1 |
| Lu, YQ | 1 |
| Qin, YY | 1 |
| Chen, YK | 1 |
| Hernandez, AV | 1 |
| Thota, P | 1 |
| Pellegrino, D | 1 |
| Pasupuleti, V | 1 |
| Benites-Zapata, VA | 1 |
| Deshpande, A | 1 |
| Penalva de Oliveira, AC | 1 |
| Vidal, JE | 1 |
| Allinson, J | 1 |
| Topping, W | 1 |
| Edwards, SG | 1 |
| Miller, RF | 1 |
| Sonneville, R | 1 |
| Schmidt, M | 1 |
| Messika, J | 1 |
| Ait Hssain, A | 1 |
| da Silva, D | 1 |
| Klein, IF | 1 |
| Bouadma, L | 1 |
| Wolff, M | 1 |
| Mourvillier, B | 1 |
| Anghel, G | 1 |
| Jordan, MK | 1 |
| Burstein, AH | 1 |
| Rock-Kress, D | 1 |
| Alfaro, RM | 1 |
| Pau, AK | 1 |
| Kovacs, JA | 1 |
| Piscitelli, SC | 1 |
| Solano Remírez, M | 1 |
| Oliván Ballabriga, AS | 1 |
| da Costa Rodríguez, GM | 1 |
| Alvarez Frías, MT | 1 |
| González Arencibia, C | 1 |
| Swaminathan, S | 1 |
| Pollett, S | 1 |
| Loblay, R | 1 |
| Macleod, C | 1 |
| Furrer, H | 1 |
| von Overbeck, J | 1 |
| Jaeger, P | 1 |
| Hess, B | 1 |
| Ferrer, S | 1 |
| Fuentes, I | 1 |
| Domingo, P | 1 |
| Muñoz, C | 1 |
| Iranzo, A | 1 |
| Barrio, JL | 1 |
| Fuster, M | 1 |
| Ris, J | 1 |
| Sambeat, MA | 1 |
| Cadafalch, J | 1 |
| Nolla, J | 1 |
| Ebrahimzadeh, A | 1 |
| Bottone, EJ | 1 |
| Hoetelmans, RM | 1 |
| Kraaijeveld, CL | 1 |
| Meenhorst, PL | 1 |
| Mulder, JW | 1 |
| Burger, DM | 1 |
| Koks, CH | 1 |
| Beijnen, JH | 1 |
| Lightman, S | 1 |
| Lynn, WA | 1 |
| Cochereau-Massin, I | 1 |
| LeHoang, P | 1 |
| Lautier-Frau, M | 1 |
| Zerdoun, E | 1 |
| Zazoun, L | 1 |
| Robinet, M | 1 |
| Marcel, P | 1 |
| Girard, B | 1 |
| Katlama, C | 1 |
| Leport, C | 1 |
1 review available for sulfadiazine and HIV Coinfection
| Article | Year |
|---|---|
A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option?
Topics: Adult; Antiprotozoal Agents; Clindamycin; Cohort Studies; Female; HIV Infections; Humans; Male; Midd | 2017 |
2 trials available for sulfadiazine and HIV Coinfection
| Article | Year |
|---|---|
A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-I | 2020 |
Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients.
Topics: Anti-Infective Agents; Area Under Curve; Cross-Over Studies; Half-Life; HIV Infections; Humans; Mode | 2004 |
11 other studies available for sulfadiazine and HIV Coinfection
| Article | Year |
|---|---|
Sulphadiazine-induced obstructive renal failure complicating treatment of HIV-associated toxoplasmosis.
Topics: Antiprotozoal Agents; Fluid Therapy; HIV Infections; Humans; Middle Aged; Nephrostomy, Percutaneous; | 2012 |
Neurologic outcomes and adjunctive steroids in HIV patients with severe cerebral toxoplasmosis.
Topics: Adult; Antiprotozoal Agents; Comorbidity; Disease Progression; Drug Therapy, Combination; Female; Gl | 2012 |
[Clinical and therapy features of ocular toxoplasmosis in patients with HIV-AIDS infection].
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Child; Drug Therapy, Combination; Female; Folic Ac | 2002 |
[Renal failure caused by sulfadiazine in a HIV patient with toxoplasmic encephalitis].
Topics: Adult; Antiprotozoal Agents; Encephalitis; Female; HIV Infections; Humans; Sulfadiazine; Toxoplasmos | 2005 |
Sulfonamide crystals and acute renal failure.
Topics: Acute Kidney Injury; AIDS-Related Opportunistic Infections; Crystallization; HIV Infections; Humans; | 2006 |
[Sulfadiazine nephrolithiasis and nephropathy].
Topics: Adult; AIDS-Related Opportunistic Infections; Bicarbonates; Fluid Therapy; HIV Infections; Humans; H | 1994 |
[Cerebral toxoplasmosis in patients with human immunodeficiency virus (HIV) infection. Clinico-radiological and therapeutic aspects in 63 patients].
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Clind | 1996 |
Persistent diarrhea caused by Isospora belli: therapeutic response to pyrimethamine and sulfadiazine.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-Infective Agents; Antitrichomonal Agents; Diarrhea | 1996 |
Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Anti-Infective Agents; Antidotes; Dideoxynucleosides; | 1997 |
Clinical microbiological case: visual problems in an HIV-positive patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Antiretroviral Therapy, | 2001 |
Ocular toxoplasmosis in human immunodeficiency virus-infected patients.
Topics: Adult; Aged; Clindamycin; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Follow-Up S | 1992 |